Medical Oncology

Prof. Dr. Taner Korkmaz

Doctor and researcher Acıbadem Maslak Hastanesi İstanbul
Lung NeoplasmsBreast NeoplasmsCarcinoma, Non-Small-Cell LungAdenocarcinomaCarcinoma, Ductal, BreastStomach Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Lung Neoplasms 9 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Breast Neoplasms 7 publications
  • Carcinoma, Non-Small-Cell Lung 5 publications
  • Adenocarcinoma 3 publications
  • Carcinoma, Ductal, Breast 2 publications
  • Stomach Neoplasms 2 publications

Person ↔ Disease

Which topics does this doctor work on?

From source

Medical areas of interest stated by the doctor on the institution profile. Source: acibadem.com.tr.

  • Ağız Kanseri
  • Baş Boyun Kanserleri
  • Beyin Tümörleri
  • Böbrek Kanseri
  • Böbrek Üstü Bezi Kanseri
  • Akciğer, Akciğer Zarı Kanserleri (Mezotelyoma) ve Diğer Torasik Kanserler
  • Dil ve Dil Kökü Kanseri
  • Anal (Makat) Kanseri
  • Burun İçi Tümörleri
  • Malign Melanom ve Diğer Deri Tümörleri
  • Akciğer Kanseri
  • Dil Kanseri

CV

Education and experience

From source

Experience

  • 2014Acıbadem Sağlık Grubuacibadem.com.tr
  • 2011 - 2014Dr. Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesiacibadem.com.tr
  • 2005 - 2008Okmeydanı Eğitim ve Araştırma Hastanesiacibadem.com.tr
  • 2004 - 2005Derince 100 Yataklı Askeri Hastanesiacibadem.com.tr
  • 2004Sağlık Bakanlığı Büyük Ada Dispanseriacibadem.com.tr

Education

  • 2012Doçent, Digeracibadem.com.tr
  • 2011Marmara Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji, Uzmanlıkacibadem.com.tr
  • 2003İstanbul Eğitim ve Araştırma Hastanesi, İç Hastalıkları, Uzmanlıkacibadem.com.tr
  • 1999Ege Üniversitesi Tıp Fakültesi, Üniversiteacibadem.com.tr

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologyacibadem.com.trFrom source
  • Department name at the sourceMeme Kliniğiacibadem.com.trFrom source
  • InstitutionAcıbadem Maslak Hastanesiacibadem.com.trFrom source
  • Area of workLung NeoplasmsExtracted from 9 publications · Model version —From source
  • Publications73 publicationsOpenAlexFrom source
  • Last synchronised4 November 2026 21:00https://www.acibadem.com.tr/doktor/taner-korkmaz/acibadem.com.tr

Scientific work

Publications on Lung Neoplasms

73 publications

  1. Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study

    Cancers, 2026

    DOI 10.3390/cancers18121979 PMID 42352512 Open-access full textSource: OpenAlex

  2. Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature

    Clinical Genitourinary Cancer, 2026

    DOI 10.1016/j.clgc.2026.102594 PMID 42349378 Source: OpenAlex

  3. Real-World Outcomes of Fosaprepitant-Containing Prophylaxis in Patients Receiving Highly and Moderately Emetogenic Chemotherapy: A Two-Center Retrospective Study

    SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital, 2026

    DOI 10.14744/semb.2026.32391 PMID 42824916 Open-access full textSource: OpenAlex

  4. Evolving Concepts and Contemporary Management of Early-Stage Breast Cancer: An Evidence-Based Approach to Grey Zones from a Comprehensive Breast Unit Part 2: Systemic Treatment

    European Journal of Breast Health, 2025

    DOI 10.4274/ejbh.galenos.2025.2025-10-2 PMID 41447641 Open-access full textSource: OpenAlex

  5. 42P Concordance of CanAssist breast with Oncotype Dx and MammaPrint in patients with early stage hormone receptor positive breast cancer

    ESMO Open, 2025

    DOI 10.1016/j.esmoop.2025.104596 Open-access full textSource: OpenAlex

  6. The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2− Breast Cancer: A Multicenter Observational Study from Turkey

    Cancers, 2025

    DOI 10.3390/cancers17091592 PMID 40361516 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  7. Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study

    Cancers, 2024

    DOI 10.3390/cancers16193389 PMID 39410009 5 citations (Europe PMC) Open-access full textSource: OpenAlex

  8. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy

    Medicine, 2024

    DOI 10.1097/md.0000000000037972 PMID 38787994 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  9. Recommendations for cyclin‑dependent kinase 4/6 inhibitor treatments in the context of co‑morbidity and drug interactions (Review)

    Oncology Letters, 2024

    DOI 10.3892/ol.2024.14278 PMID 38385117 8 citations (Europe PMC) Open-access full textSource: OpenAlex

  10. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

    BMC Cancer, 2023

    DOI 10.1186/s12885-023-10609-8 PMID 36765293 18 citations (Europe PMC) Open-access full textSource: OpenAlex

View all 73 publications